{"id":6566,"date":"2024-01-11T16:22:23","date_gmt":"2024-01-11T10:52:23","guid":{"rendered":"http:\/\/door2dream.com\/2023_projects\/equantx\/?page_id=6566"},"modified":"2024-03-04T19:00:40","modified_gmt":"2024-03-04T13:30:40","slug":"oncoarct","status":"publish","type":"page","link":"http:\/\/door2dream.com\/2023_projects\/equantx\/oncoarct\/","title":{"rendered":"OncoArcT
(Oncology and Rare Disease Insights)"},"content":{"rendered":"

[vc_row css_animation=”slideInUp” bg_type=”image” parallax_style=”vcpb-default” bg_image_repeat=”no-repeat”][vc_column][vc_single_image image=”9004″ img_size=”medium” alignment=”center”]

<\/div>
<\/p>\n

Comprehensive Insight Coverage on Onco Indications <\/strong><\/p>\n

<\/div><\/div>

<\/div>

Accessing to standardized and validated information on drug usage forassessing patterns of countryspecific drug utilization<\/h2><\/div>
<\/p>\n

We offer comprehensive insights into major and rare oncology indications through our OncoArct solutions, a subscription-based service designed for pharmaceutical companies seeking in-depth knowledge of drug utilization rates and treatment landscapes.Our indication-specific reports are precisely developed, presenting a comparative analysis of the latest market landscape on a product-by-product and company-by-company basis. This detailed assessment is the result of exhaustive analysis by our Competitive Intelligence (CI) experts, incorporating scientific, clinical, and commercial factors gathered through primary and secondary research.
\nOur top-tier OncoArct subscription support ensures quarterly updates, integrating fresh data from conferences, insights
\nfrom primary experts, KOL interviews, and other reliable sources<\/div><\/div>

<\/div>
<\/div>

Key Features<\/h4><\/div><\/div>[vc_row_inner][vc_column_inner width=”1\/4″]
\t\t
[vc_single_image image=”6892″ alignment=”center” css_animation=”slideInUp” css=”.vc_custom_1705142400895{border-radius: 20px !important;}”]
<\/div>
<\/p>\n

Country-Specific Prescribing Practices<\/strong><\/p>\n

<\/div><\/div>[vc_column_text css_animation=”slideInUp”]<\/p>\n

OncoArct excels in identifying and describe country-specific prescribing practices, providing pharmaceutical companies with a detailed understanding of regional variations in drug utilization<\/p>\n

<\/h3>\n

[\/vc_column_text]\t\t<\/div><\/div>[\/vc_column_inner][vc_column_inner width=”1\/4″]

\t\t
[vc_single_image image=”6891″ alignment=”center” css_animation=”slideInUp” css=”.vc_custom_1705142410820{border-radius: 20px !important;}”]
<\/div>
<\/p>\n

Influential Factors
\nAssessment<\/strong><\/div><\/div>[vc_column_text css_animation=”slideInUp”]<\/p>\n

This platform goes beyond the surface, delving into the factors that shape prescribing practices, offering pharmaceutical companies a comprehensive analysis of the influences guiding healthcare professionals’ decisions.<\/p>\n

<\/h3>\n

[\/vc_column_text]\t\t<\/div><\/div>[\/vc_column_inner][vc_column_inner width=”1\/4″]

\t\t
[vc_single_image image=”6893″ alignment=”center” css_animation=”slideInUp” css=”.vc_custom_1705142421739{border-radius: 20px !important;}”]
<\/div>
<\/p>\n

Treatment Regimen Adherence Analysis<\/strong><\/p>\n

<\/div><\/div>[vc_column_text css_animation=”slideInUp”]<\/p>\n

OncoArct scrutinizes treatment adherence and non-adherence patterns, providing pharmaceutical companies with actionable data to optimize patient care strategies and enhance treatment outcomes<\/p>\n

<\/h3>\n

[\/vc_column_text]\t\t<\/div><\/div>[\/vc_column_inner][vc_column_inner width=”1\/4″]

\t\t
[vc_single_image image=”6899″ alignment=”center” css_animation=”slideInUp” css=”.vc_custom_1705142433853{border-radius: 20px !important;}”]
<\/div>
<\/p>\n

Cost-Effectiveness
\nEvaluation<\/strong><\/div><\/div>[vc_column_text css_animation=”slideInUp”]<\/p>\n

OncoArct provides a robust assessment of the cost-effectiveness of drugs, empowering pharmaceutical companies to make informed decisions on pricing strategies and market positioning.<\/p>\n

<\/h3>\n

[\/vc_column_text]

<\/div>\t\t<\/div><\/div>[\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner]
<\/div>[\/vc_column_inner][\/vc_row_inner]
<\/div>

Get Data-driven Insights on<\/h4><\/div><\/div>[vc_tta_tabs alignment=”center” active_section=”1″ css_animation=”slideInUp” css=”.vc_custom_1709382391916{background-color: #e0f5f9 !important;}”][vc_tta_section title=”Epidemiology” tab_id=”1704972560387-10d40785-d912″][vc_column_text]<\/p>\n

The Epidemiology section of OncoArct offers comprehensive insights into the prevalence, incidence, mortality, and survival rates associated with specific diseases. This data-driven analysis enables pharmaceutical companies to understand the broader health landscape, aiding strategic decision-making<\/p>\n

[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Diagnosis & Treatment” tab_id=”1704972560421-fb5fb0d0-e433″][vc_column_text]This section delves into the details of diagnosis pathways, standard of care, treatment guidelines, and the patient journey. By providing a holistic view of the diagnostic and treatment landscape, OncoArct equips pharmaceutical companies with crucial information for developing targeted and effective healthcare solutions[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Regulatory Landscape” tab_id=”1704972819535-33ffe050-ed86″][vc_column_text]OncoArct’s Regulatory Landscape section offers detailed information on approval timelines, study outcomes, and the probability of success. This data empowers pharmaceutical companies with a deeper understanding of the regulatory environment, facilitating informed decision-making in product development[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Trial Analysis” tab_id=”1704972820781-7c967943-7a20″][vc_column_text]Covering clinical study outcomes across various phases (I, II, III, & IV), trial objectives, and phase-specific details, the Trial Analysis and benchmarking section provides a comprehensive overview of ongoing and completed trials. This data aids pharmaceutical companies in evaluating the effectiveness and progress of clinical research initiatives[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Drug Utilization” tab_id=”1704972821768-01397529-1d96″][vc_column_text]The Drug Utilization section provides detailed insights into patient share, diagnosis by types\/classification of diseases, molecular biomarkers, stages and severity, lines of therapy, treatment modalities, and utilization by specific products and products class. This granular information is invaluable for optimizing marketing strategies and enhancing product positioning[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”RWE Data” tab_id=”1704972823071-a3490cb0-18f8″][vc_column_text]Real-world evidence (RWE) data within OncoArct encompasses trial outcome data and patient outcome data. This section contributes real-world insights, allowing pharmaceutical companies to bridge the gap between clinical trials and real-world patient experiences, ultimately informing evidence-based decision-making[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Summary” tab_id=”1704972907908-e5c4b7be-5c73″][vc_column_text]The Summary section of OncoArct offers user-defined summaries and facilitates report generation. This feature ensures that users can distill complex data into actionable insights tailored to their specific needs, streamlining the decision-making process[\/vc_column_text][\/vc_tta_section][\/vc_tta_tabs]

<\/div>[\/vc_column][\/vc_row][vc_row css=”.vc_custom_1708339442270{padding-top: 14px !important;padding-right: 14px !important;padding-bottom: 14px !important;padding-left: 14px !important;background-color: #e0f5f9 !important;}”][vc_column][vc_row_inner][vc_column_inner]
<\/div>

Oncology Coverage<\/h4><\/div><\/div>[\/vc_column_inner][\/vc_row_inner][vc_row_inner css=”.vc_custom_1705153567828{margin-bottom: -6px !important;background-color: #dbdbdb !important;}”][vc_column_inner]
<\/div>
<\/p>\n

Our best in class competitive intelligence coverage across the indications and supporting commercial, and medical affairs teams worldwide<\/p>\n

<\/div><\/div>[\/vc_column_inner][\/vc_row_inner][vc_row_inner css=”.vc_custom_1705144539175{background-color: #ffffff !important;}”][vc_column_inner]

<\/div>
Solid Tumors<\/strong><\/span><\/div><\/div>[\/vc_column_inner][\/vc_row_inner][vc_row_inner css=”.vc_custom_1705144539175{background-color: #ffffff !important;}”][vc_column_inner width=”1\/3″]
    \n
  • Brain Cancer<\/li>\n
  • Bladder<\/li>\n
  • Cervix<\/li>\n
  • Colon<\/li>\n
  • Colorectal<\/li>\n
  • Cutaneous T-cell lymphoma (CTCL)<\/li>\n
  • Oesophagus<\/li>\n
  • Gastric<\/li>\n
  • Gastrointestinal Stromal Tumors (GIST)<\/li>\n<\/ul>\n<\/div>[\/vc_column_inner][vc_column_inner width=”1\/3″]
      \n
    • Hodgkin Lymphoma<\/li>\n
    • Kidney<\/li>\n
    • Liver<\/li>\n
    • Lymphoid Leukaemia, Chronic (CLL)<\/li>\n
    • Melanoma (Skin)<\/li>\n
    • Multiple Myeloma<\/li>\n
    • Myelodysplatic Syndrome (MDS)<\/li>\n
    • Ovary<\/li>\n
    • HCC<\/li>\n<\/ul>\n<\/div>[\/vc_column_inner][vc_column_inner width=”1\/3″]
        \n
      • Renal Cell Carcinoma<\/li>\n
      • Rectum<\/li>\n
      • Sarcoma<\/li>\n
      • Thyroid<\/li>\n
      • Uterus<\/li>\n
      • Osteosarcoma<\/li>\n
      • Pancreas<\/li>\n
      • Prostrate<\/li>\n
      • Head and Neck<\/li>\n<\/ul>\n<\/div>[\/vc_column_inner][\/vc_row_inner][vc_row_inner css=”.vc_custom_1705144539175{background-color: #ffffff !important;}”][vc_column_inner width=”1\/3″]
        <\/div>
        Breast Cancer<\/strong><\/span><\/div><\/div>
        <\/div>
          \n
        • HR-positive \/ HER2-negative<\/li>\n
        • HR-positive \/ HER2-positive<\/li>\n
        • HR-negative \/ HER2-positive<\/li>\n
        • HR-negative \/ HER2-negative<\/li>\n<\/ul>\n<\/div>
          <\/div>
          T-Cell Lymphoma<\/strong><\/span><\/div><\/div>
          <\/div>
            \n
          • Peripheral T-Cell Lymphoma (PTCL)<\/li>\n
          • Cutaneous T-cell lymphoma (CTCL)<\/li>\n<\/ul>\n<\/div>
            <\/div>
            Oral Cavity and Pharynx<\/strong><\/span><\/div><\/div>
            <\/div>
              \n
            • Lip<\/li>\n
            • Tongue<\/li>\n
            • Small Intestine<\/li>\n
            • Soft Tissue including Heart<\/li>\n
            • Stomach<\/li>\n
            • Testis<\/li>\n<\/ul>\n<\/div>[\/vc_column_inner][vc_column_inner width=”1\/3″]
              <\/div>
              Non-Hodgkin Lymphoma<\/strong><\/span><\/div><\/div>
              <\/div>
                \n
              • Chronic Lymphocytic Leukaemia\/Small Lymphocytic<\/li>\n
              • Lymphoma (CLL\/SLL)<\/li>\n
              • Diffuse Large B-Cell Lymphoma (DLBCL)<\/li>\n
              • Follicular Lymphoma<\/li>\n<\/ul>\n<\/div>
                <\/div>
                Solid Tumors<\/strong><\/span><\/div><\/div>
                <\/div>
                  \n
                • HR-positive \/ HER2-negative<\/li>\n
                • HR-positive \/ HER2-positive<\/li>\n
                • HR-negative \/ HER2-positive<\/li>\n
                • HR-negative \/ HER2-negative<\/li>\n<\/ul>\n<\/div>
                  <\/div>
                  Neuro Endocrine Tumors<\/strong><\/span><\/div><\/div>
                  <\/div>
                  \n
                    \n
                  • Gastro-entero-pancreatic sites (Digestive system)<\/li>\n
                  • Rectum<\/li>\n
                  • Jejunum\/ileum<\/li>\n
                  • Pancreas<\/li>\n
                  • Stomach<\/li>\n<\/ul>\n
                      \n
                    • Colon<\/li>\n
                    • Duodenum<\/li>\n
                    • Cecum<\/li>\n
                    • Appendix<\/li>\n
                    • Liver<\/li>\n<\/ul>\n<\/div>\n<\/div>[\/vc_column_inner][vc_column_inner width=”1\/3″]
                      <\/div>
                      Leukaemia<\/strong><\/span><\/div><\/div>
                      <\/div>
                        \n
                      • Acute Lymphocytic Leukaemia (ALL)<\/li>\n
                      • Acute Myeloid Leukaemia (AML)<\/li>\n
                      • Chronic Lymphocytic Leukaemia (CLL)<\/li>\n<\/ul>\n<\/div>
                        <\/div>
                        Lung Cancer<\/strong><\/span><\/div><\/div>
                        <\/div>
                          \n
                        • Non-Small Cell Lung Cancer<\/li>\n
                        • Small Cell Lung Cancer<\/li>\n<\/ul>\n<\/div>
                          <\/div>
                          Non-melanoma skin cancer (NMSC)<\/strong><\/span><\/div><\/div>
                          <\/div>
                            \n
                          • Basal cell carcinoma (BCC)<\/li>\n
                          • Cutaneous squamous cell carcinoma (cSCC)<\/li>\n<\/ul>\n<\/div>[\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column]
                            <\/div>[\/vc_column][\/vc_row][vc_row full_width=”stretch_row” bg_type=”bg_color” css=”.vc_custom_1709537080639{margin-bottom: -76px !important;background: #e8e8e8 url(http:\/\/door2dream.com\/2023_projects\/equantx\/wp-content\/uploads\/2024\/03\/frty.png?id=10542) !important;}”][vc_column css_animation=”slideInUp” css=”.vc_custom_1709537060457{margin-top: 24px !important;margin-right: 24px !important;margin-bottom: 24px !important;margin-left: 24px !important;padding-top: 14px !important;padding-right: 14px !important;padding-bottom: 14px !important;padding-left: 14px !important;border-radius: 10px !important;}”]
                            <\/div>

                            Communicate With Us<\/h2><\/div>
                            <\/p>\n

                            Contact us to discuss pricing options and find the right plans for you<\/strong><\/span><\/strong><\/p>\n

                            <\/div><\/div>[vc_column_text]\n

                            \n

                            <\/p>

                              <\/ul><\/div>\n
                              \n
                              \n\n\n\n\n\n\n<\/div>\n
                              \n\t
                              \n\t\t

                              \n\t\t

                              \n\t\t